1 active not recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Celcuity Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole - Breast Cancer | Phase 3 | Recruiting | Celcuity Inc | 1180 | 2025-07-24 | 2026-10-09 |
| Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) Gedatolisib, Palbociclib, Fulvestrant - Breast Cancer | Phase 3 | Active not recruiting | Celcuity Inc | 701 | 2022-12-08 | 2026-02-10 |
Breast Neoplasms (2) · Neoplasm Metastasis (2)
Fulvestrant (2) · gedatolisib (2) · palbociclib (2) · Alpelisib (1) · Letrozole (1) · ribociclib (1)
Argentina (2) · Australia (2) · Belgium (2) · Bulgaria (2) · Czechia (2) · France (2) · Germany (2) · Greece (2) · Hungary (2) · Italy (2) · Mexico (2) · Poland (2) · Romania (2) · South Korea (2) · Spain (2)
Nadene Zack (1)